Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $257.21 USD
Change Today -0.32 / -0.12%
Volume 1.8M
VRX On Other Exchanges
Symbol
Exchange
VRX is not on other exchanges.
As of 8:04 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

Transactions by VALEANT PHARMACEUTICALS INTE (VRX) in the last 6 months

Announced 07/23/15
Commonwealth Laboratories, Inc., U.S. and Canadian Business
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) reached an agreement to acquire U.S. and Canadian business from Commonwealth Laboratories, Inc. on July 23, 2015. The deal provides for an up-front purchase price to be paid by Valeant on closing, with the opportunity for additional sales-based milestones payments. Commonwealth’s existing management team will remain in place and will continue to drive the strategic direction of the company. Commonwealth’s current ...
Read More


VRX's price was unchanged after the transaction was announced on 07/23/15.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Commonwealth Laboratories Inc.
 
Announced 07/17/15
800.00M for Amoun Pharmaceutical Company S.A.E.
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into a definitive agreement to acquire Amoun Pharmaceutical Company S.A.E. for $800 million on July 17, 2015. As part of consideration, some additional contingent payments will be made by Valeant. Valeant intends for Amoun to serve as a platform for further expansion in the broader Middle East and North Africa. The deal is subject to customary closing conditions and is expected to close in third quarter of ...
Read More


VRX's price was unchanged after the transaction was announced on 07/17/15.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Al Razzi Holding K.S.C.C.
Capital International, Inc.
CIPEF IV
CIPEF V
Financial Advisor
The Goldman Sachs Group, Inc.
 
Announced 07/13/15
28.00M for Unilens Vision Inc.
Merger/Acquisition

Valeant Pharmaceuticals International, Inc. (TSX:VRX) entered into a definitive agreement to acquire Unilens Vision Inc. (OTCPK:UVIC) for $22.4 million in cash on July 10, 2015. Under the terms, Valeant Pharmaceuticals is offering $12.75 in cash for each outstanding common stock and option of Unilens. The transaction will terminate if not completed by October 31, 2015. Unilens will be required to pay a termination fee of $0.7 million equivalent to 3.5% of the equity ...
Read More


VRX's price was unchanged after the transaction was announced on 07/13/15.
Investor / Buyer
Valeant Pharmaceuticals International, Inc.
Creditor / Lender
Baker Street Capital Management LLC
Legal Advisor
Baker & Hostetler LLP
 
Announced 03/9/15
3.30B for Valeant Pharmaceuticals International, Inc.
Merger/Acquisition

Pershing Square Capital Management, L.P. through its fund Pershing Square Holdings, Ltd. (ENXTAM:PSH) acquired 4.9% stake in Valeant Pharmaceuticals International, Inc. (TSX:VRX) for $3.3 billion on March 9, 2015. Pershing acquired 16.5 million shares of Valeant. As on March 20, 2015, the transaction received early termination of antitrust approval. Tim Burt of StockWell Communications acted as public relations advisor in the deal. Davies Ward Phillips & Vineberg LLP ...
Read More


VRX's price was unchanged after the transaction was announced on 03/9/15.
 
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VRX:US $257.21 USD -0.32

VRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.50 USD -0.19
Astellas Pharma Inc ¥1,922 JPY +0.50
Bristol-Myers Squibb Co $65.34 USD -0.30
Celgene Corp $131.47 USD +0.22
Eli Lilly & Co $84.14 USD -0.37
View Industry Companies
 

Industry Analysis

VRX

Industry Average

Valuation VRX Industry Range
Price/Earnings 100.0x
Price/Sales 9.5x
Price/Book 13.6x
Price/Cash Flow 34.6x
TEV/Sales 6.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALEANT PHARMACEUTICALS INTE, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.